Polyarginine and PEG-AEYLR comodified nanostructured lipid carrier: 10mol% uncleavable PEG-AEYLR showed no shielding effect to polyarginine in vitro while maintaining good tumor targeting in vivo

References

• Li SD, Huang L. Stealth nanoparticles: high density but sheddable PEG is a key for tumor targeting. J Control Release. 2010;145:178–181.
   PubMed Web of Science ®Google Scholar
• Lo CL, Chou MH, Lu PL, et al. The effect of PEG-5K grafting level and particle size on tumor accumulation and cellular uptake. Int J Pharm. 2013;456:424–431.
   PubMedGoogle Scholar
• Stepniewski M, Pasenkiewicz-Gierula M, Rog T, et al. Study of PEGylated lipid layers as a model for PEGylated liposome surfaces: molecular dynamics simulation and Langmuir monolayer studies. Langmuir. 2011;27:7788–7798.
   PubMed Web of Science ®Google Scholar
• Koren E, Apte A, Jani A, et al. Multifunctional PEGylated 2C5-immunoliposomes containing pH-sensitive bonds and TAT peptide for enhanced tumor cell internalization and cytotoxicity. J Control Release. 2012;160:264–273.
   PubMed Web of Science ®Google Scholar
• Tabatabaei Mirakabad FS, Akbarzadeh A, Milani M, et al. A Comparison between the cytotoxic effects of pure curcumin and curcumin-loaded PLGA-PEG nanoparticles on the MCF-7 human breast cancer cell line. Artif Cells, Nanomed Biotechnol. 2016;44:423–430.
   PubMed Web of Science ®Google Scholar
• Kim SK, Huang L. Nanoparticle delivery of a peptide targeting EGFR signaling. J Control Release. 2012;157:279–286.
   PubMed Web of Science ®Google Scholar
• Arabi L, Badiee A, Mosaffa F, et al. Targeting CD44 expressing cancer cells with anti-CD44 monoclonal antibody improves cellular uptake and antitumor efficacy of liposomal doxorubicin. J Control Release. 2015;220:275–286.
   PubMed Web of Science ®Google Scholar
• Dubey PK, Singodia D, Vyas SP. Polymeric nanospheres modified with YIGSR peptide for tumor targeting. Drug Deliv. 2010;17:541–551.
   PubMed Web of Science ®Google Scholar
• Kaur S, Mehra NK, Jain K, et al. Development and evaluation of targeting ligand-anchored CNTs as prospective targeted drug delivery system. Artif Cells Nanomed Biotechnol. 2017;45:242–250.
   PubMed Web of Science ®Google Scholar
• Raagel H, Saalik P, Hansen M, et al. CPP-protein constructs induce a population of non-acidic vesicles during trafficking through endo-lysosomal pathway. J Control Release. 2009;139:108–117.
   PubMed Web of Science ®Google Scholar
• Torchilin VP. Tat peptide-mediated intracellular delivery of pharmaceutical nanocarriers. Adv Drug Deliv Rev. 2008;60:548–558.
   PubMed Web of Science ®Google Scholar
• Trehin R, Merkle HP. Chances and pitfalls of cell penetrating peptides for cellular drug delivery. Eur J Pharm Biopharm. 2004;58:209–223.
   PubMed Web of Science ®Google Scholar
• Ruoslahti E. Tumor penetrating peptides for improved drug delivery. Adv Drug Deliv Rev. 2016;pii:S0169-409X(16)30094-1.
   PubMed Web of Science ®Google Scholar
• Sun M, Gao Y, Zhu Z, et al. A systematic in vitro investigation on poly-arginine modified nanostructured lipid carrier: pharmaceutical characteristics, cellular uptake, mechanisms and cytotoxicity. Asian J Pharm Sci. 2016;12:51–58.
   PubMed Web of Science ®Google Scholar
• Park K. Arginine-rich CPPs for improved drug delivery to tumors. J Control Release. 2012;159:153.
   PubMed Web of Science ®Google Scholar
• Han C, Li Y, Sun M, et al. Small peptide-modified nanostructured lipid carriers distribution and targeting to EGFR-overexpressing tumor in vivo. Artif Cells Nanomed Biotechnol. 2014;42:161–166.
   PubMed Web of Science ®Google Scholar
• Han CY, Yue LL, Tai LY, et al. A novel small peptide as an epidermal growth factor receptor targeting ligand for nanodelivery in vitro. Int J Nanomedicine. 2013;8:1541–1549.
   PubMed Web of Science ®Google Scholar
• Yang X, Zhao L, Almasy L, et al. Preparation and characterization of 4-dedimethylamino sancycline (CMT-3) loaded nanostructured lipid carrier (CMT-3/NLC) formulations. Int J Pharm. 2013;450:225–234.
   PubMed Web of Science ®Google Scholar
• Zhang W, Li X, Ye T, et al. Design, characterization, and in vitro cellular inhibition and uptake of optimized genistein-loaded NLC for the prevention of posterior capsular opacification using response surface methodology. Int J Pharm. 2013;454:354–366.
   PubMed Web of Science ®Google Scholar
• Wang XB, Zhou HY. Molecularly targeted gemcitabine-loaded nanoparticulate system towards the treatment of EGFR overexpressing lung cancer. Biomed Pharmacother. 2015;70:123–128.
   PubMed Web of Science ®Google Scholar
• Abe M, Kuroda Y, Hirose M, et al. Inhibition of autophosphorylation of epidermal growth factor receptor by small peptides in vitro. Br J Pharmacol. 2006;147:402–411.
   PubMed Web of Science ®Google Scholar
• Liu J, Zhang B, Luo Z, et al. Enzyme responsive mesoporous silica nanoparticles for targeted tumor therapy in vitro and in vivo. Nanoscale. 2015;7:3614–3626.
   PubMed Web of Science ®Google Scholar
• Lee H. Molecular dynamics studies of PEGylated single-walled carbon nanotubes: the effect of PEG size and grafting density. J Phys Chem C. 2013;117:26334–26341.
   Web of Science ®Google Scholar
• Kang MH, Park MJ, Yoo HJ, et al. RIPL peptide (IPLVVPLRRRRRRRRC)-conjugated liposomes for enhanced intracellular drug delivery to hepsin-expressing cancer cells. Eur J Pharm Biopharm. 2014;87:489–499.
   PubMed Web of Science ®Google Scholar
• Bhattacharjee S. DLS and zeta potential - what they are and what they are not? J Control Release. 2016;235:337–351.
   PubMed Web of Science ®Google Scholar
• Aditya NP, Macedo AS, Doktorovova S, et al. Development and evaluation of lipid nanocarriers for quercetin delivery: a comparative study of solid lipid nanoparticles (SLN), nanostructured lipid carriers (NLC), and lipid nanoemulsions (LNE). Food Sci Technol. 2014;59:115–121.
   Web of Science ®Google Scholar
• Guo P, Song S, Li Z, et al. In vitro and in vivo evaluation of APRPG-modified angiogenic vessel targeting micelles for anticancer therapy. Int J Pharm. 2015;486:356–366.
   PubMedGoogle Scholar
• Yoshizawa Y, Kono Y, Ogawara K, et al. PEG liposomalization of paclitaxel improved its in vivo disposition and anti-tumor efficacy. Int J Pharm. 2011;412:132–141.
   PubMed Web of Science ®Google Scholar